Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CRISPR THERAPEUTICS AG

(CRSP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

CRISPR Therapeutics : Citigroup Lifts CRISPR Therapeutics to Neutral From Sell, Price Target to $132 From $55

06/14/2021 | 07:11am EDT


© MT Newswires 2021
All news about CRISPR THERAPEUTICS AG
10:30aCRISPR THERAPEUTICS : Chardan Adjusts Price Target on CRISPR Therapeutics to $17..
MT
03:24aCRISPR THERAPEUTICS : Files for Mixed-Securities Shelf Offering
MT
07/29CRISPR THERAPEUTICS : More than 45 patients have been dosed with CTX001™ a..
PU
07/29CRISPR THERAPEUTICS : Management's Discussion and Analysis of Financial Conditio..
AQ
07/29CRISPR THERAPEUTICS AG : Results of Operations and Financial Condition, Financia..
AQ
07/29CRISPR THERAPEUTICS : Earnings Flash (CRSP) CRISPR THERAPEUTICS AG Posts Q2 Reve..
MT
07/29CRISPR THERAPEUTICS : Earnings Flash (CRSP) CRISPR THERAPEUTICS AG Reports Q2 EP..
MT
07/29CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2021 ..
GL
07/23DGAP-NEWS : Il settore delle biotecnologie -2-
DJ
07/23PRESS RELEASE : Solid second quarter for the -2-
DJ
More news
Financials (USD)
Sales 2021 902 M - -
Net income 2021 373 M - -
Net cash 2021 2 608 M - -
P/E ratio 2021 25,6x
Yield 2021 -
Capitalization 9 053 M 9 053 M -
EV / Sales 2021 7,15x
EV / Sales 2022 107x
Nbr of Employees 410
Free-Float 86,8%
Chart CRISPR THERAPEUTICS AG
Duration : Period :
CRISPR Therapeutics AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CRISPR THERAPEUTICS AG
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 119,00 $
Average target price 163,00 $
Spread / Average Target 37,0%
EPS Revisions
Managers and Directors
Samarth Kulkarni Chief Executive Officer & Director
Rodger Novak Chairman & President
Michael John Tomsicek Chief Financial & Accounting Officer
Tony W. Ho Executive VP, Head-Research & Development
Stephen R. Kennedy Head-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
CRISPR THERAPEUTICS AG-22.28%9 535
MODERNA, INC.230.85%138 784
LONZA GROUP AG21.77%56 806
IQVIA HOLDINGS INC.38.81%47 656
CELLTRION, INC.-29.39%31 282
SEAGEN INC.-16.10%26 668